For most people, a mosquito bite results in a few days of fever or uncomfortable swelling. However, for millions of people infected with chikungunya, the bite can trigger what doctors call "ghost"pain"—excruciating joint pain that lasts long after the virus has left the body. Researchers at Griffith University in Australia think they are close to producing a vaccination that could prevent long-term damage before it occurs. 

Chikungunya is a mosquito-borne viral disease that has rapidly spread over Asia, Africa, and portions of Europe, with India remaining one of the most impacted. Symptoms of the infection include a rapid fever, chills, headache, rash, and severe joint and muscular pain. While fevers usually subside within a few days, joint pain may not always go away. 

"Up to 60% of patients experience long-term joint pain, which can last months or years and resembles rheumatoid arthritis," said Professor Bernd Rehm of Griffith's Institute for Biomedicine and Glycomics. 

This lasting agony occurs because chikungunya infects more than just the blood. After entering the body, the virus attacks joint tissues, muscle fibres, and connective tissue. Dr Rehm says, "Once this procedure occurs, we start to see direct tissue damage, intense inflammation, and immune-mediated attacks resembling autoimmune responses." Even after the virus has been eliminated, the immune system can continue to attack the joints, resulting in chronic pain that feels like arthritis but is not caused by an active infection — known as ghost pain. 

To address this issue, the Griffith University team devised a novel vaccine technique known as a "decoy" tactic. Instead of using a weakened or destroyed virus, the researchers modified E. coli, a harmless bacterium, to make tiny synthetic biopolymer particles that closely resembled the outer surface of the chikungunya virus. 

"The synthetic biopolymer particles, adjuvant-free E2-BP-E1, closely mimicked the actual virus and induced an immune response," according to Professor Rehm. 

Simply said, the vaccination tells the immune system what the virus looks like without producing sickness. The body learns to detect and attack chikungunya early on, before it causes joint damage. The immune system recognises the particles as a legitimate threat, absorbing them efficiently and developing robust antiviral defences. 

This technique is essential because there is presently no licensed vaccine for chikungunya, and treatment is mostly focused on symptom relief. Many people in India continue to ask: will chikungunya discomfort linger for years, is chikungunya arthritis permanent, and is there any way to avoid it? According to current studies, prevention may now be possible. 

The study, "Adjuvant-free biopolymer particles mimicking the Chikungunya virus surface induce protective immunity," was published in Biomaterials, a peer-reviewed publication. Following favourable laboratory results, the researchers want to proceed with clinical development. 

The next phase will be human safety trials, followed by larger research to see how effective the vaccine is. While it may take several years before the method becomes widely available, scientists believe it will be especially useful in tropical nations where mosquito-borne diseases are prevalent. 

For populations continually struck by chikungunya epidemics, the idea of ending lifelong joint agony is a significant advance. If successful, the vaccine might alter chikungunya from a disease that takes away mobility for years to one that can be safely avoided.